MYRIAD GENETICS INC (MYGN)
US62855J1043 - Common Stock
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine....
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
Myriad Genetics provides update on discussions with UnitedHealthcare regarding medical policy for pharmacogenetic testing....
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members....
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
Prolaris, MyRisk, and Precise Tumor Testing Validated Across Cancer Stages, Elevating Company’s Comprehensive Patient-Centric Solutions
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
Myriad Genetics’ full suite of urologic oncology products is elevated by updated NCCN prostate cancer guidelines....
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
Presentations include analytical validation of Myriad’s high-definition tumor informed MRD assay for breast cancer and its Breast Cancer Risk Assessment Tool MyRisk® with RiskScore®
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
Myriad Genetics, Inc. announced it will present new data at the 2024 San Antonio Breast Cancer Symposium....
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
Prolaris Remains a Long-Standing Fixture in the Guidelines for 10th Year Running
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
Myriad Genetics announced Prolaris prostate cancer prognostic test is classified by the NCCN as an advanced tool in the fight against prostate cancer....
RSI Alert: Myriad Genetics (MYGN) Now Oversold
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
Agreement will expand worldwide access and better position Myriad’s GIS as a potential companion diagnostic across multiple potential tumor types
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
Myriad Genetics announces incorporation of its proprietary HRD platform in Illumina’s updated comprehensive gene panel assay, TruSight™ Oncology 500 v2....
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
Myriad Genetics announced Prequel® Prenatal Screen is now available at eight weeks into pregnancy....
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc....
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
SneakPeek®, the first at-home early fetal sex test for use at six weeks, is now available at over 8,800 retail locations nationwide
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
Myriad Genetics announced SneakPeek is now available over the counter in more than 8,800 retail locations....
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and progress on payor...
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc....
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
Myriad Genetics comments on UnitedHealthcare’s updated medical policy for pharmacogenetic testing...
Myriad Genetics Enters Oversold Territory (MYGN)
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
Management will also participate in two upcoming investor healthcare conferences
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
Myriad Genetics, Inc. (NASDAQ: MYGN) will hold its third quarter earnings conference call on Thursday, Nov. 7, 2024 at 4:30 pm ET....
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
Myriad Genetics announced a strategic partnership with jscreen to advance health equity and genetic testing access....
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
Myriad Genetics and Flatiron Health partner to make genetic testing more accessible with EMR integration...